# Merge Labs, PBC

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/merge-labs-pbc

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.merge.io/
- Total disclosed funding: $252M
- Latest round: Seed (Jan 15, 2026)
- Investors on record: 4

## About

Merge Labs, PBC, based in the US, develops advanced brain-computer interfaces (BCIs) to enhance cognitive abilities by bridging biological and artificial intelligence, focusing on innovative technologies for various end-users.Founded in 2025, Merge Labs, PBC is headquartered in San Francisco, US, specializing in creating brain-computer interfaces. The company secured USD 250 mn in Seed funding from Bain Capital and OpenAI on January 15, 2026, marking its first significant funding round. The founder's history is not disclosed, and there are no mentions of prior companies or changes in business strategy.Merge Labs focuses on developing advanced brain-computer interfaces (BCIs) designed to enhance human cognitive abilities and experiences by bridging biological and artificial intelligence. Their core offerings include innovative technologies that utilize molecular connections to neurons rather than traditional electrodes, enabling high-bandwidth interaction with the brain. The BCIs aim to facilitate various end-use cases, such as restoring lost abilities due to injury or disease, enhancing mental health, and fostering deeper connections between individuals. Currently, these products are targeted toward patients requiring rehabilitation, healthcare providers, and research institutions, with a future outlook aimed at broader applications across various sectors. Merge Labs anticipates expanding its reach into global markets, ensuring that their technologies are accessible and beneficial to a diverse client base.The revenue model of Merge Labs is structured around partnerships and direct-to-consumer sales, with an emphasis on collaborations with healthcare facilities and research organizations. The company aims to position its flagship products within the healthcare sector, where they can be integrated into rehabilitation programs and mental health initiatives. Transactions typically involve licensing agreements or subscriptions for ongoing access to their innovative BCIs and associated services, ensuring a consistent revenue stream. The pricing strategy is designed to reflect the advanced technology and significant benefits provided by their products, catering to both institutional clients and individual users who are seeking to enhance their cognitive capacities. As the company develops its market presence, it focuses on creating real products that resonate with users, driving both usage and revenue generation.In January 2026, Merge Labs, PBC raised USD 250 mn in Seed funding from OpenAI and Bain Capital to develop new non-invasive brain-computer interface technologies that integrate with advanced AI to enhance human capabilities. The company plans to launch these new products in the near future, focusing on enhancing human cognitive abilities. Merge Labs is also targeting expansion into international markets, with specific plans to reach healthcare providers in Europe and Asia by the end of 2027.

## Funding rounds

- Seed, Jan 15, 2026, $252M — Bain Capital, Fifty Years, Openai Startup Fund Management, Interface Fund

## Investors

- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Seed
- Fifty Years (https://capitalatlas.ai/funds/fifty-years) — Seed
- Openai Startup Fund Management (https://capitalatlas.ai/funds/openai-startup-fund-management) — Seed
- Interface Fund — Seed